Peptide Vera

Buffalo, United States

Trastuzumab, marketed as Herceptin, is a prescription biologic medicine used to treat cancers that overexpress the HER2 (human epidermal growth factor receptor 2) protein. The 150 mg strength is supplied as a lyophilized powder for intravenous (IV) infusion and is widely used in oncology practice.

Trastuzumab is a humanized monoclonal antibody (IgG1) that specifically targets the HER2 receptor, which is overproduced in certain aggressive cancers. HER2 overexpression promotes rapid tumor growth and spread.

Herceptin binds to the HER2 receptor on cancer cells and:

• Blocks HER2-driven signaling pathways that promote tumor cell growth

• Marks cancer cells for immune destruction through antibody-dependent cellular cytotoxicity (ADCC)

• Enhances the effectiveness of chemotherapy and other anti-HER2 agents

Trastuzumab is approved for:

• HER2-positive breast cancer

  • Early-stage (adjuvant and neoadjuvant)

  • Metastatic breast cancer

• HER2-positive metastatic gastric or gastroesophageal junction cancer

HER2 positivity must be confirmed by an approved diagnostic test before treatment.

email: peptidevera@

Etoposide Injection 100 mg is a prescription anticancer (chemotherapy) medication belonging to the podophyllotoxin derivative class. It is used in oncology to treat various malignancies, often as part of combination chemotherapy regimens, and is administered under strict medical supervision.

• Small cell lung cancer

• Testicular cancer

• Lymphomas (Hodgkins and non-Hodgkins)

• Leukemias and other solid tumors (as prescribed)

(For use by qualified healthcare professionals only.)

WHATSAPP: +1 (917) 724-2641

ELREXFIO (elranatamabbcmm) is a bispecific antibody biologic used to treat adults with relapsed or refractory multiple myeloma after multiple prior therapies. It is given as a subcutaneous solution in readytouse vials and is approved for use under stringent safety monitoring due to immune activation effects.

Bizengri (zenocutuzumab-zbco) is a targeted cancer therapy specifically a bispecific monoclonal antibody designed to treat certain rare, genetically defined solid tumors.

Bizengri (generic name zenocutuzumab-zbco) is a biologic drug that targets two cancer-related receptors HER2 and HER3 on the surface of tumor cells. It uses a proprietary dock and block bispecific mechanism to bind HER2 and block HER3 from interacting with neuregulin 1 (NRG1) fusion proteins, which can drive cancer growth.

How It Works

• Bispecific antibody: binds simultaneously to HER2 and HER3.

• Blocks NRG1 fusion signaling: prevents the cancer-driving effects of NRG1 fusions, which can activate downstream pathways that promote tumor cell proliferation and survival.

Bizengri is approved (under accelerated approval) for adults with:

• Advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion after prior systemic therapy.

• Advanced, unresectable or metastatic pancreatic adenocarcinoma with an NRG1 gene fusion after prior systemic therapy.

Perjeta (pertuzumab) is a prescription biologic medicine used in the treatment of HER2-positive breast cancer. It is a monoclonal antibody designed to work in combination with trastuzumab (Herceptin) and chemotherapy to improve treatment outcomes in patients with aggressive HER2-driven disease.

Perjeta inhibits cancer growth by:

• Preventing HER2 dimerization with other HER family receptors (HER1, HER3, HER4)

• Blocking downstream signaling pathways responsible for tumor growth and survival

• Enhancing immune-mediated destruction of cancer cells

Email: peptidevera@

Tecvayli 153mg Injection contains the active substance Teclistamab. It is an anticancer medication classified as a bispecific monoclonal antibody.

Tecvayli Injection is used for the treatment of adult patients with relapsed or refractory multiple myeloma, a type of cancer affecting plasma cells in the bone marrow, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Tecvayli works by targeting and binding to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells.

Inform your doctor before starting treatment with Tecvayli 153mg Injection, as it may lead to serious side effects such as cytokine release syndrome (CRS), neurotoxicities, and infections. Regular monitoring and prompt management of these conditions are crucial during therapy.

Make sure to inform your physician of all the medicines you are taking before starting treatment with Tecvayli 153mg Injection. Report any symptoms such as difficulty breathing, cough, fever, chest pain, weakness, or seizures to your doctor.

Uses of Tecvayli 153mg Injection

To treat adult patients with relapsed or refractory multiple myeloma (a type of cancer affecting plasma cells in the bone marrow) who have previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Therapeutic Effects of Tecvayli 153mg Injection

Tecvayli 153mg Injection works by targeting and binding specifically to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells, thereby inhibiting their growth and proliferation.

Interaction of Tecvayli 153mg Injection with other drugs

Inform your healthcare professional about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.

Certain medications interacting with Tecvayli 153mg Injection may reduce effectiveness by causing undesirable side effects.

More Information about Tecvayli 153mg Injection

• Store Tecvayli 153mg Injection in the refrigerator at 2C to 8C. Do not freeze.
• Keep out of sight and reach of children and pets.
• Store in the original container to protect from light.
• Monitor patients regularly for signs and symptoms of cytokine release syndrome (CRS) and neurological toxicities.
• Conduct regular blood tests to detect any abnormalities and other potential side effects, as directed by the healthcare provider.

How to consume Tecvayli 153mg Injection

A healthcare professional administers Tecvayli 153mg Injection via intravenous infusion. The infusion is given over a specified duration as per your doctor's treatment schedule. Do not self-administer the injection or alter the infusion schedule without consulting your healthcare provider.

Email: peptidevera@